688443 Stock Overview
A biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Chongqing Genrix Biopharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥27.19 |
| 52 Week High | CN¥45.51 |
| 52 Week Low | CN¥22.11 |
| Beta | 0 |
| 1 Month Change | 4.10% |
| 3 Month Change | 18.58% |
| 1 Year Change | -24.87% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -20.08% |
Recent News & Updates
Shareholder Returns
| 688443 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 0.4% | -3.0% | -2.1% |
| 1Y | -24.9% | -19.0% | 9.8% |
Return vs Industry: 688443 underperformed the CN Biotechs industry which returned -19% over the past year.
Return vs Market: 688443 underperformed the CN Market which returned 9.8% over the past year.
Price Volatility
| 688443 volatility | |
|---|---|
| 688443 Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 13.0% |
| 10% least volatile stocks in CN Market | 5.8% |
Stable Share Price: 688443 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688443's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 674 | n/a | www.genrixbio.com |
Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China. It develops GR1501, a monoclonal antibody for the treatment of axial spondylarthritis; GR1801, an anti-rabies virus G protein bispecific antibody; GR1802, an anti-IL-4Ra monoclonal antibody; GR1603, a monoclonal antibody for systemic lupus erythematosus; GR2002 an anti-TSLP bispecific antibody; WM1R3, a family receptor bispecific antibody; GR2001, a monoclonal antibody; GR2201, a monoclonal antibody for VZV infection; GR1803, a bispecific antibody for multiple myeloma; GR1901, a bispecific antibody; WM202 a bispecific antibody; WM215, a single-domain antibody; GR1401, an anti-EGFR monoclonal antibody; and GR1405 an anti-PD-L1 monoclonal antibody. The company was founded in 2015 and is based in Chongqing, China.
Chongqing Genrix Biopharmaceutical Co., Ltd. Fundamentals Summary
| 688443 fundamental statistics | |
|---|---|
| Market cap | CN¥9.97b |
| Earnings (TTM) | -CN¥779.42m |
| Revenue (TTM) | CN¥13.56m |
735.2x
P/S Ratio-12.8x
P/E RatioIs 688443 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688443 income statement (TTM) | |
|---|---|
| Revenue | CN¥13.56m |
| Cost of Revenue | CN¥2.08m |
| Gross Profit | CN¥11.48m |
| Other Expenses | CN¥790.90m |
| Earnings | -CN¥779.42m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.13 |
| Gross Margin | 84.64% |
| Net Profit Margin | -5,747.82% |
| Debt/Equity Ratio | 31.8% |
How did 688443 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 18:52 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Chongqing Genrix Biopharmaceutical Co., Ltd. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peng Zou | China International Capital Corporation Limited |
| null null | China International Capital Corporation Limited |
| Ziyu He | China International Capital Corporation Limited |